Results 101 to 110 of about 12,098 (189)

Nanotechnology‐Enhanced Approaches for Early Cancer Diagnosis

Nano Select, Volume 7, Issue 1, January 2026.
Conventional MRI and PET provide limited sensitivity and contrast for precise brain lesion detection. In contrast, radiolabeled nanoparticlebased PET imaging enables enhanced signal specificity and sensitivity. By integrating multifunctional nanoprobes, this platform improves multimodal imaging performance, allowing more accurate visualization of ...
Jongmoo Lee, Jiyu Kim, Eunhye Cho, Junyeop Jeong, Jayeon Song, Mikyung Kang   +5 more
wiley   +1 more source

Oncogenic RIT1 mutations in lung adenocarcinoma [PDF]

, 2014
Lung adenocarcinoma is comprised of distinct mutational subtypes characterized by mutually exclusive oncogenic mutations in RTK/RAS pathway members KRAS, EGFR, BRAF and ERBB2, and translocations involving ALK, RET and ROS1.
Andres, D A, Berger, A H, Duke, F, Imielinski, M, Kaplan, N, Meyerson, M, Shi, G-X, Wala, J   +7 more
core   +1 more source

Effusion‐Dominant Pulmonary Sarcomatoid Carcinoma Without a Primary Mass: A Case Report

Respirology Case Reports, Volume 14, Issue 1, January 2026.
We describe a patient with high‐grade sarcomatoid carcinoma presenting as malignant pleural effusion without a primary mass. This case highlights the diagnostic challenges, aggressive clinical course, and importance of early biopsy. We also review the limited literature describing similar presentations.
Sze Kye Teoh, Yen Shen Wong, Yiet Fai Ng, Yu Wei Cheah, Suhashini Ganapaty, Saiful Safuan Md Sani   +5 more
wiley   +1 more source

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain

Scientific Reports
The ROS1 receptor tyrosine kinase (RTK) possesses the largest extracellular amino-terminal domain (ECD) among the human RTK family, yet the mechanisms regulating its activation are not fully understood. While chimeric ROS1 fusion proteins, resulting from
Kristen Jones, Clare Keddy, Chelsea Jenkins, Katelyn Nicholson, Ujwal Shinde, Monika A. Davare   +5 more
doaj   +1 more source

Non‐Small Cell Lung Cancer Patients With Tumors ≤ 2 Cm Are Suitable for Wedge Resection or Segmentectomy: A Real‐World Study

Thoracic Cancer, Volume 17, Issue 1, January 2026.
Wedge resection is an optimal choice for NSCLCs ≤ 2 cm, especially for GGO‐dominant tumors. However, segmentectomy is more appropriate when the CTR is > 0.25. ABSTRACT Background The role of wedge resection in the treatment of non‐small cell lung cancer (NSCLC) with solid components ≤ 2 cm remains controversial.
Yuetian Pan, Xincheng Li, Ying Ji, Bin Hu, Jinbai Miao   +4 more
wiley   +1 more source

Structural Aspects of the ROS1 Kinase Domain and Oncogenic Mutations

Crystals
Protein kinases function as pivotal regulators in biological events, governing essential cellular processes through the transfer of phosphate groups from ATP molecules to substrates.
Juliana F. Vilachã, Tsjerk A. Wassenaar, Siewert J. Marrink   +2 more
doaj   +1 more source

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?

Lung Cancer: Targets and Therapy, 2023
Danielle Brazel,1 Saihong Ignatius Ou1,2 1University of California Irvine School of Medicine, Department of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Saihong Ignatius Ou, University ...
Brazel D, Ou SI
doaj  

Comparative Analysis of a Dual DNA–RNA Panel and a DNA‐Only Panel for Sarcoma: Real‐World Data From a Nationwide Genomic Database

Cancer Science, Volume 117, Issue 1, Page 156-168, January 2026.
Dual DNA–RNA panel with matched tumor–normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma. ABSTRACT Next‐generation sequencing‐based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor‐only DNA panels from single ...
Eiji Nakata, Kiichiro Ninomiya, Tatsunori Osone, Daisuke Ennishi, Shuta Tomida, Tomohiro Fujiwara, Toshiyuki Kunisada, Mashu Futagawa, Akira Hirasawa, Shinichi Toyooka, Toshifumi Ozaki   +10 more
wiley   +1 more source

FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan‐Asian Study

Hepatology Research, Volume 56, Issue 1, Page 78-88, January 2026.
FGFR2 Alterations in Young Adults with cholangiocarcinoma was common. Intrahepatic cholangiocarcinoma (ICC) is a rare liver cancer, typically seen in older adults. This study focused on younger patients across Asia, examining changes in the FGFR2 gene that may drive cancer growth.
Yuta Maruki, Yasushi Yatabe, Chiharu Mizoguchi, Kathleen Yasmin de Almeida, Aumkhae Sookprasert, Charuwan Akewanlop, Ming‐Huang Chen, Ekaphop Sirachainan, Dao Van Tu, Rozita Abdul Malik, Chaiyut Charoentum, Hwoei Fen Soo Hoo, Suhana Yusak, Tsung‐Hao Liu, Rangasamy Ramachandran, Patrapim Sunpaweravong, Pei Jye Voon, Najihah Abu Bakar, Junki Mizusawa, Hitomi Sumiyoshi Okuma, Kenichi Nakamura, Chigusa Morizane, Takuji Okusaka   +22 more
wiley   +1 more source

CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing

Thoracic Cancer, 2018
ROS1 rearrangement is a validated therapeutic driver gene in non‐small cell lung cancer (NSCLC) and represents a small subset (1–2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi‐targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated remarkable efficacy in ROS1 ...
You‐cai Zhu, Yue‐fen Zhou, Wen‐xian Wang, Chun‐wei Xu, Wu Zhuang, Kai‐qi Du, Gang Chen   +6 more
openaire   +2 more sources